Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.46 |
| ▸ | CTSK | P43235 | 11/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8270413 | 0.87 | CTSS (0.49) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL7433111 | 0.86 | CTSK (0.49) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL5074699 | 0.84 | CTSS (0.50) | CTSSCTSKCTSLCTSB | |
| SCHEMBL5078711 | 0.84 | CTSS (0.54) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL31023450 | 0.84 | CTSS (0.43) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL1515640 | 0.83 | CTSS (0.48) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL355405 | 0.83 | CTSS (0.48) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL18614278 | 0.83 | CTSS (0.48) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL2726957 | 0.82 | CTSK (0.43) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL21284248 | 0.82 | CTSK (0.43) | CTSSCTSKCTSLCTSBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580802-B2 | Pyrrolo[2,3-D]pyrimidines as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2532667-A1 | Deazapurines useful as inhibitors of janus kinases | Vertex Pharmaceuticals Incorporated (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-1931674-B1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMA (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20070207995-A1 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207995-A1 | Deazapurines useful as inhibitors of Janus kinases | JAK1, JAK3, JAK2 | CTSS 4247/4885CTSK 3334/4885CTSL 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.